Last reviewed · How we verify
DA-5219
DA-5219 is a selective serotonin 5-HT4 receptor partial agonist that enhances gastric motility and accelerates gastric emptying.
DA-5219 is a selective serotonin 5-HT4 receptor partial agonist that enhances gastric motility and accelerates gastric emptying. Used for Functional dyspepsia, Gastroparesis.
At a glance
| Generic name | DA-5219 |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | 5-HT4 receptor partial agonist |
| Target | 5-HT4 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
By acting as a partial agonist at the 5-HT4 receptor, DA-5219 increases acetylcholine release in the enteric nervous system, thereby promoting coordinated gastric muscle contractions. This mechanism facilitates the movement of food from the stomach into the small intestine, making it useful for treating functional gastrointestinal disorders characterized by impaired gastric motility.
Approved indications
- Functional dyspepsia
- Gastroparesis
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-5219 CI brief — competitive landscape report
- DA-5219 updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI